Dosage Form Design & Development, Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, USA.
Dosage Form Design & Development, Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, USA.
J Pharm Sci. 2022 Jun;111(6):1605-1613. doi: 10.1016/j.xphs.2022.03.010. Epub 2022 Mar 19.
High-throughput analysis of low-volume samples for detection of subvisible particles (SVPs) in biologic formulations remains an unmet need in the pharmaceutical industry. Some commonly used methods, such as light obscuration and microflow imaging, for SVP analysis are not high throughput and require significant amounts of sample volume, which may impede the collection of SVP data when therapeutic protein amounts are limited, typically during early stages of formulation development. We evaluated backgrounded membrane imaging (BMI) as an orthogonal method for SVP analysis and identified critical experimental parameters. Protein concentration, sample viscosity, and membrane coverage area had to be adjusted for each sample, especially those with high protein concentrations. A comparative analysis of particle counts obtained from BMI, light obscuration, and microflow imaging for five protein samples revealed that particle counts obtained with BMI were significantly higher than those acquired with the other two techniques for all particle size categories. BMI could not accurately count particles in protein-containing samples, as the image analysis software could not accurately trace the boundaries of translucent particles. Based on our results, BMI could be used as an orthogonal method for particle characterization when sample material is limited, such as during the early stages of formulation development or screening.
高通量分析生物制剂中低体积样品中的亚可见颗粒 (SVPs) 仍然是制药行业未满足的需求。一些常用的 SVP 分析方法,如光遮挡和微流成像,不是高通量的,需要大量的样品体积,当治疗性蛋白数量有限时,这可能会阻碍 SVP 数据的收集,通常在制剂开发的早期阶段。我们评估了背景膜成像 (BMI) 作为 SVP 分析的正交方法,并确定了关键的实验参数。必须针对每个样品调整蛋白浓度、样品粘度和膜覆盖面积,特别是那些蛋白浓度高的样品。对五种蛋白样品的 BMI、光遮挡和微流成像获得的颗粒计数进行比较分析表明,对于所有粒径类别,BMI 获得的颗粒计数明显高于其他两种技术获得的颗粒计数。BMI 无法准确地对含有蛋白的样品中的颗粒进行计数,因为图像分析软件无法准确地追踪半透明颗粒的边界。基于我们的结果,当样品材料有限时,例如在制剂开发或筛选的早期阶段,BMI 可以用作颗粒特征的正交方法。